Abstract
Programmed cell death (apoptosis) is a key tumor suppressor mechanism. Consequently, most if not all cancers develop mechanisms to abolish or circumvent this genetic program. Besides enabling malignant transformation and tumor progression, defects in apoptosis can result in resistance to cytotoxic cancer therapies. Much progress has been made in the delineation of the molecular pathways leading to apoptosis. This allows the identification of target molecules and lead compounds to develop novel therapies, which make use of this intrinsic death program for the treatment of cancer. Here, we review the current understanding of apoptotic signal transduction pathways, and strategies of their therapeutic modulation in relation to lymphoma and other cancers.
Keywords: BH3-only proteins, p53 Gene Transfer, pro-apoptotic genes, TNF receptor superfamily, Mouse-double-minute-2 (MDM-2)
Current Drug Targets
Title: Therapeutic Targeting of Apoptotic Pathways in Cancer
Volume: 7 Issue: 10
Author(s): Johannes Meiler and Martin Schuler
Affiliation:
Keywords: BH3-only proteins, p53 Gene Transfer, pro-apoptotic genes, TNF receptor superfamily, Mouse-double-minute-2 (MDM-2)
Abstract: Programmed cell death (apoptosis) is a key tumor suppressor mechanism. Consequently, most if not all cancers develop mechanisms to abolish or circumvent this genetic program. Besides enabling malignant transformation and tumor progression, defects in apoptosis can result in resistance to cytotoxic cancer therapies. Much progress has been made in the delineation of the molecular pathways leading to apoptosis. This allows the identification of target molecules and lead compounds to develop novel therapies, which make use of this intrinsic death program for the treatment of cancer. Here, we review the current understanding of apoptotic signal transduction pathways, and strategies of their therapeutic modulation in relation to lymphoma and other cancers.
Export Options
About this article
Cite this article as:
Meiler Johannes and Schuler Martin, Therapeutic Targeting of Apoptotic Pathways in Cancer, Current Drug Targets 2006; 7 (10) . https://dx.doi.org/10.2174/138945006778559175
DOI https://dx.doi.org/10.2174/138945006778559175 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
Current Genomics HIV-1 Vectors: Fulfillment of Expectations, Further Advancements, and Still A Way To Go
Current HIV Research World Health Organization Classification of Myelodysplastic Syndromes
Current Pharmaceutical Design Chlorophylls and their Derivatives Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Fluoroquinolones in Pediatrics
Current Drug Therapy Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Dedication: Commendation of Diligence
Current Gene Therapy Human Mesenchymal Stem Cells (hMSCs) as Targets of DNA Damaging Agents in Cancer Therapy
Current Cancer Drug Targets Hepcidin: Biological Activity, Analytical Methods in Biological Fluids, Clinical Applications and Antagonists. A Short Review
Current Pharmaceutical Analysis Lenalidomide – Current Understanding of Mechanistic Properties
Anti-Cancer Agents in Medicinal Chemistry Advances in the Development of Site-Specific Antibody-Drug Conjugation
Anti-Cancer Agents in Medicinal Chemistry Selective Photodynamic Effects on Breast Cancer Cells Provided by p123 Pluronic®- Based Nanoparticles Modulating Hypericin Delivery
Anti-Cancer Agents in Medicinal Chemistry Design of New Drug Molecules to be Used in Reversing Multidrug Resistance in Cancer Cells
Current Cancer Drug Targets In Vitro Antitumoral Activity of Palladium(II) and Platinum(II) Complexes with O,O'-Dialkyl Esters of Ethylene-bis(S)-Leucine
Letters in Drug Design & Discovery Effect of Drugs in Cells and Tissues by NMR Spectroscopy
Current Topics in Medicinal Chemistry Management of Early Stage Chronic Myeloid Leukemia: State-of-the-art Approach and Future Perspectives
Current Cancer Drug Targets Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design Old Wine in a New Bottle: The Warburg Effect and Anticancer Mechanisms of Resveratrol
Current Pharmaceutical Design Cholinergic Receptors as Target for Cancer Therapy in a Systems Medicine Perspective
Current Molecular Medicine